PABPC1L Inhibitors
PABPC1L (Poly(A) Binding Protein Cytoplasmic 1 Like) inhibitors comprise various compounds that indirectly influence the protein's expression and function through distinct cellular mechanisms. Key inhibitors such as Rapamycin, Actinomycin D, Cycloheximide, and Emetine impact crucial cellular processes including mRNA translation and DNA transcription, which are integral to PABPC1L function. Rapamycin, an mTOR inhibitor, specifically affects mRNA translation and stability, altering PABPC1L-related pathways. Actinomycin D and Cycloheximide, by inhibiting DNA transcription and eukaryotic protein synthesis respectively, can decrease the expression and translation of PABPC1L, thus affecting its role in mRNA regulation. Emetine, also targeting protein synthesis, further contributes to the reduced translation of PABPC1L.
Additionally, compounds like Fluorouracil, Camptothecin, Oxaliplatin, Puromycin dihydrochloride, Bortezomib, Suberoylanilide Hydroxamic Acid, and Chloroquine modulate various aspects of DNA/RNA synthesis, protein translation, and cellular degradation pathways, all of which can indirectly impact PABPC1L. Fluorouracil and Camptothecin, affecting DNA and RNA synthesis, along with Oxaliplatin, which causes DNA damage, could influence PABPC1L expression. Puromycin dihydrochloride disrupts protein synthesis, affecting PABPC1L translation. Bortezomib, as a proteasome inhibitor, might influence the degradation and turnover of PABPC1L, while Suberoylanilide Hydroxamic Acid, by altering gene expression patterns, could impact its expression. Chloroquine, affecting lysosomal degradation pathways, may also play a role in modulating PABPC1L degradation. These diverse mechanisms underscore the complex regulation of PABPC1L, highlighting the intricate interplay of cellular processes in the regulation of proteins involved in mRNA processing and translation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Inhibits mTOR, a kinase involved in mRNA translation and stability, potentially affecting PABPC1L-related pathways. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Binds to DNA and inhibits RNA synthesis, potentially decreasing the expression of PABPC1L and its associated functions. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Inhibits eukaryotic protein synthesis, potentially reducing the translation of PABPC1L and affecting its function. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
This compound inhibits thymidylate synthase, leading to a depletion of the deoxythymidine triphosphate (dTTP) pool. The reduction in dTTP availability results in impaired DNA synthesis and repair, indirectly leading to the inhibition of PABPC1L expression as it relies on these cellular processes for its production and function. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
Doxorubicin intercalates into DNA, creating breaks and hindering the transcription process. This interference with DNA replication and transcription can indirectly inhibit the expression of PABPC1L, as its synthesis is dependent on these fundamental cellular processes. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
As an inhibitor of DNA topoisomerase I, Camptothecin hampers DNA replication and transcription. This inhibition disrupts the normal synthesis of proteins, including PABPC1L, thereby reducing its expression levels in cells. | ||||||
Oxaliplatin | 61825-94-3 | sc-202270 sc-202270A | 5 mg 25 mg | $110.00 $386.00 | 8 | |
Oxaliplatin forms DNA adducts, causing DNA damage. The resultant stress and DNA repair mechanisms that are triggered can indirectly lead to a reduction in PABPC1L expression, as the cell's resources are redirected to address the DNA damage. | ||||||
Puromycin dihydrochloride | 58-58-2 | sc-108071 sc-108071B sc-108071C sc-108071A | 25 mg 250 mg 1 g 50 mg | $40.00 $210.00 $816.00 $65.00 | 394 | |
Puromycin causes premature chain termination during protein synthesis. By interrupting the translation process, it indirectly inhibits the synthesis of PABPC1L, as the protein cannot be fully formed and functional. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor, potentially affecting the degradation and turnover of PABPC1L. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
An HDAC inhibitor, Vorinostat alters chromatin structure and overall gene expression patterns. This alteration can lead to a downregulation of PABPC1L expression, as changes in histone acetylation levels can suppress the transcription of certain genes. | ||||||